Lasofoxifene Tartrate (AZU-101)

Phase 2Small molecule

Lasofoxifene Tartrate (AZU-101) is one of 16 small molecule programs targeting Postmenopausal Women. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Postmenopausal WomenNot yet recruiting

Postmenopausal WomenPhase 2

Not yet recruiting

Competition

Competitive Landscape

17 competitors in Postmenopausal Women

#DrugCompanyPhaseTrials

Afinitor

Novartis

Phase 2

4 2

Depo-Testosterone

AAzurity Pharmaceuticals

Phase 2

1 3

Cortrosyn

Novartis

Phase 1

1 4

Decadron

AAspen Global Incorporated

Phase 1

1 5

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 1

1 6

Orgalutran

OOrganon and Co

Phase 1

1 7

Phytoestrogen

CCairo University

Phase 3

1 8

Factrel

Ferring

Phase 1

1 9

AGA2118

AAngitia Biopharmaceuticals

Phase 2

2 10

Lasofoxifene Tartrate (AZU-101)

AAzure Biotech Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1/2Not yet recruiting

Postmenopausal Women

NCT06197568

Clinical

Trials by Indication[1]

Postmenopausal Women1 trial

Open-Label Study of Vaginal AZU-101 in Postmenopausal Women

Not yet recruiting·AAzure Biotech Inc.·Phase 1/2·NCT06197568·35 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Lasofoxifene Tartrate (AZU-101). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lasofoxifene Tartrate (AZU-101) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lasofoxifene Tartrate (AZU-101). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Azure Biotech Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAzure Biotech Inc.

Lasofoxifene Tartrate (AZU-101)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Postmenopausal Women1 trial

References

Drug Info

Quick Facts

Related News